Efficacy of Liraglutide Therapy in Patients With IPAA

NCT04763564 on ClinicalTrials.gov · last registry update 2024-07-23

Stopped early, having planned 8 participants. Completed 16 October 2023.

Status: TERMINATED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of North Carolina, Chapel Hill
Sponsor type: Other
Enrollment: 8
Started: 2022-03-22
Primary completion: 2023-10-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean % Reduction of Bowel Frequency in Percent of the Mean 7-day Bowel Frequency After 4 Weeks of Therapy on Liraglutide vs Placebo Compared to Baseline .

Conditions studied

Pouchitis · Irritable Pouch Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.